Capital A Wealth Management LLC Acquires Shares of 27,033 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Capital A Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 27,033 shares of the company's stock, valued at approximately $596,000. Teva Pharmaceutical Industries makes up 1.0% of Capital A Wealth Management LLC's holdings, making the stock its 20th biggest holding.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC raised its position in Teva Pharmaceutical Industries by 31.7% in the third quarter. Barclays PLC now owns 427,595 shares of the company's stock valued at $7,705,000 after purchasing an additional 102,848 shares during the period. Park Avenue Securities LLC raised its position in Teva Pharmaceutical Industries by 23.2% in the fourth quarter. Park Avenue Securities LLC now owns 12,434 shares of the company's stock valued at $274,000 after purchasing an additional 2,341 shares during the period. DGS Capital Management LLC raised its position in Teva Pharmaceutical Industries by 12.6% in the fourth quarter. DGS Capital Management LLC now owns 15,340 shares of the company's stock valued at $338,000 after purchasing an additional 1,713 shares during the period. Fifth Third Bancorp raised its position in Teva Pharmaceutical Industries by 6,682.6% in the fourth quarter. Fifth Third Bancorp now owns 18,720 shares of the company's stock valued at $413,000 after purchasing an additional 18,444 shares during the period. Finally, Blue Trust Inc. raised its position in Teva Pharmaceutical Industries by 42.3% in the fourth quarter. Blue Trust Inc. now owns 20,809 shares of the company's stock valued at $459,000 after purchasing an additional 6,190 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Bank of America lifted their price objective on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Wall Street Zen raised Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $21.00 to $23.00 in a research note on Monday, May 12th. Truist Financial assumed coverage on Teva Pharmaceutical Industries in a research note on Wednesday. They issued a "buy" rating and a $25.00 price objective for the company. Finally, Hsbc Global Res raised Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $24.50.

Teva Pharmaceutical Industries Stock Down 4.3%

TEVA traded down $0.76 on Friday, hitting $16.77. 19,852,269 shares of the company were exchanged, compared to its average volume of 10,116,307. Teva Pharmaceutical Industries Limited has a twelve month low of $12.47 and a twelve month high of $22.80. The company has a market cap of $19.01 billion, a price-to-earnings ratio of -11.57, a price-to-earnings-growth ratio of 1.44 and a beta of 0.62. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a 50-day moving average price of $15.52 and a two-hundred day moving average price of $17.36.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.99 billion. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Teva Pharmaceutical Industries's revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.48 EPS. On average, equities analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.